EGFR(表皮生长因子受体)基因在HPV阴性肿瘤中频繁突变,但在HPV阳性肿瘤中很少出现异常。
While the EGFR(epidermal growth factor receptor) gene is frequently altered in HPV-negative tumors in smokers, it is rarely abnormal in HPV-positive tumors.表皮生长因子受体是一种蛋白质,被发现在细胞表面上,并参与细胞的生长,传播和复制。
EGFR is a protein that is found on the surface of cells and is involved in cellular growth, spread, and replication.表皮生长因子受体(EGFR)抑制剂治疗方法:EGFRs是蛋白质某些细胞,包括癌细胞的表面上发现。
Epidermal growth factor receptor(EGFR) inhibitor therapy: EGFRs are proteins found on the surface of certain cells, including cancer cells.EGFR(表皮生长因子受体)参与了多种类型的的发展和进展癌和肠癌(结肠癌尤其是)。
EGFR(Epidermal Growth Factor Receptors) are involved in the development and progression of many types of cancer and bowel cancer(colon carcinoma) in particular.对某些表皮生长因子受体基因突变和影响患者治疗反应的检测也正在探索中。
The role of testing for certain EGFR gene mutations and the mutations' affect on a patient's responsiveness to treatment is also being explored.Combinations with other parts of speech
表皮生长因子受体家族-在过去十年里,许多生长因子及其受体被发现在原发性乳腺癌表达。
Epidermal Growth Factor Receptor Family- over the last decade, many growth factors and their receptors have been found to be expressed in primary breast cancers.由于表皮生长因子受体存在于一些肺癌细胞中,厄洛替尼已经在癌症进展尽管化疗的患者中进行了研究。
As epidermal growth factor receptors are present in some lung cancer cells, erlotinib has been studied in patients whose cancers have progressed despite chemotherapy.乳腺癌:大多数乳腺癌患有过量的称为人表皮生长因子受体的蛋白质。
Breast cancer:most breast cancer has an excess of a protein called human epidermal growth factor receptor.MarkerTherapeutics公司正在开发TPIV100/110,正在进行II期临床试验,用于治疗人类表皮生长因子受体2乳腺癌;
The company is developing TPIV100/110, which is in PhaseII clinical trial to treat human epidermal growth factor receptor 2 breast cancer;至15%的美国非小细胞肺癌患者携带EGFR(表皮生长因子受体)突变。
Ten to 15 percent of U.S. patients withnon-small-cell lung cancer carry the EGFR(epidermal growth factor receptor) mutation.结直肠癌:这些癌症产生过多的称为(EGFR)表皮生长因子受体的蛋白质。
Colorectal cancer:These cancers make too much of a protein called(EGFR) epidermal growth factor receptor.我们还收集了以下亚组的数据:亚洲种族和正面表皮生长因子受体(EGFR)突变。
We also collected data for the following subgroups:Asian ethnicity and positive epidermal growth factor receptor(EGFR) mutation.表皮生长因子受体可以随时在你的医疗保健提供商计算的要求。
The eGFR can always be calculated at your healthcare provider's request.这些是:RAF1,表皮生长因子受体(EGFR)和CDK4。
These are: RAF1, the epidermal growth factor receptor(EGFR) and CDK4.Tinagl1通过阻止称为表皮生长因子受体基因(EGFR)的肿瘤促进蛋白的作用来治疗癌症。
Tinagl1 tackles cancer bystopping the action of a tumor-promoting protein known as epidermal growth factor receptor gene(EGFR).这种突变影响表皮生长因子受体(EGFR),它是细胞表面的开关,导致细胞不受控制的生长和扩散。
This mutation affects the epidermal growth factor receptor(EGFR), which is a switch on the surface of the cell leading to uncontrolled growth and spread.表皮生长因子受体(EGFR)是一种细胞的蛋白质,它在促进细胞生长方面发挥着重要的作用。
The epidermal growth factor receptor(EGFR) is a protein found on cells that plays a vital role in promoting cell growth..现在研究发现一种特殊的PHD蛋白质PHD3还控制了表皮生长因子受体(EGFR)。
A special PHD protein, PHD3, also controls the epidermal growth factor receptor(EGFR).Raf由RasGTP酶激活,其激活由RTK(例如表皮生长因子受体)诱导。
Raf is activated by the Ras GTPase,whose activation is induced by RTKs such as the epidermal growth factor receptor.表皮生长因子受体检测不具诊断意义,但可帮助医生更多的了解肿瘤特点,评估患者总体预后,并确定治疗方案。
EGFR testing is not diagnostic, but it helps the doctor understand more about the tumor's characteristics, evaluate a patient's overall prognosis, and determine treatment options.年4月13日,维也纳)EGFR(表皮生长因子受体)特别参与许多类型的癌症和肠癌(结肠癌)的发展和进展。
Vienna, 13 April 2017: Epidermal Growth Factor Receptors are involved in the development and progression of many types of cancer and bowel cancer(colon carcinoma) in particular.在过去的几年中,针对表皮生长因子受体(EGFR)在促进NSCLC研究、治疗和患者预后方面发挥了核心作用。
Targeting the epidermal growth factor receptor(EGFR) has played a central role in advancing NSCLC research, treatment, and patient outcome over the last several years.表皮生长因子受体是ErbB受体家族家族的成员之一,ErbB家族是包含四种紧密联系蛋白的亚家族,这四种蛋白分别是受体酪氨酸激酶类:EGFR(ErbB-1)、HER2/c-neu(ErbB-2)、Her3(ErbB-3)以及Her4(ErbB-4)。
The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR(ErbB-1), HER2/neu(ErbB-2), Her 3(ErbB-3) and Her 4(ErbB-4).HER2是人表皮生长因子受体(HER/EGFR/ERBB)家族的成员。
HER2 is a member of the human epidermal growth factor receptor(HER/EGFR/ERBB) family.HER2是表皮生长因子受体(EGFR/ErbB)家族中的成员之一。
HER2 is a member of the human epidermal growth factor receptor(HER/EGFR/ERBB) family.HER2,也称为CD340,是人表皮生长因子受体(HER/EGFR/ERBB)家族的成员。
HER2, also known as CD340, is a member of the human epidermal growth factor receptor(HER/EGFR/ERBB) family.研究人员认为,表皮生长因子受体的激活可以导致FN14基因表达和活性的增加。
The researchers believe that activation of EGFR can lead to increased expression and activity of the Fn14 gene.当您被诊断患有某些侵袭性肿瘤,您的医生希望知道表皮生长因子受体是否在肿瘤中过度表达时。
When you have been diagnosed with certain invasive cancers andyour doctor wants to determine whether EGFR is being over-expressed in the tumor.也直接磷酸化蛋白质像RGS16,激活其GTP酶的活性可能是耦合的表皮生长因子受体信号转导的G蛋白偶联受体信号。
Also directly phosphorylates other proteins like RGS16,activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling.表皮生长因子受体(EGFR)家族是一个复杂的信号转导网络的核心是几个关键的细胞过程的一部分。
The EGFR family is part of a complex signal-transduction network that is central to several critical cellular processes.